The Hepatitis C Price War Begins: Gilead Plays To Win By Signing With CVS

January 9, 2015 7:45 PM

16 0

After considerable anticipation, the hepatitis C price war is finally underway. The opening salvo was fired late last year by AbbVie (NYSE:ABBV), who negotiated a discount for its Viekira Pak medication. Express Scripts (NASDAQ:ESRX), granted Viekira Pak exclusivity as a quid pro quo, barring its members from accessing Gilead's (NASDAQ:GILD) Sovaldi and Harvoni medications.

Much about AbbVie's recent price reduction remains unknown, perhaps casting doubt as to whether this even constitutes a price war. Indeed, pharmacy benefit managers (PBMs) routinely receive discounts on branded pharmaceuticals and one could argue that Express Scripts' removal of Gilead's medications...

Read more

To category page